Queensland has ruled out lifting its ban on puberty blockers for transgender young people, despite new interim advice from Australia’s peak health research body supporting their use.
Earlier today, the National Health and Medical Research Council (NHMRC) released interim advice from its year-long review into the safety and effectiveness of puberty blockers, finding they can be appropriately used in the treatment of transgender young people. The council’s full report is due in 2028.
Federal Health Minister Mark Butler said he hoped Queensland and the Northern Territory, the two jurisdictions that have imposed restrictions on the treatment, would closely consider the findings.
“I am very confident that every state government, no matter their political persuasion, will consider the advice of our pre-eminent authority very closely,” he said.

However, within hours, Queensland ruled out any policy change.
Queensland Health Minister Tim Nicholls said the state government had “already undertaken an independent review and made a clear decision on the provision of these treatments in our public hospitals”.
“Our position remains unchanged and we will continue to prioritise the health, safety and wellbeing of young Queenslanders,” he said.
The Northern Territory has also ruled out any change in policy despite the advice from the national health body.
In 2025, Queensland accepted recommendations outlined in a review commissioned from former Victorian chief scientist Dr Ruth Vine. The 530-page report found the evidence supporting the use of puberty blockers and gender-affirming hormone therapy was “extremely limited”.
Queensland introduced its ban after the United Kingdom released the Cass Review, an examination of gender-related healthcare for children and young people. The state government’s restriction on the provision of puberty blockers in public health services is scheduled to remain in place until 2031.





